Drug Trial Radar · NCT05061719
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
812
Actual
Start
Oct 8, 2021
Primary completion
Oct 14, 2024
Study completion Oct 23, 2024
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, fixed dose, 26 week study of patients with MDD. Eligible patients from the lead-in studies will enter the Open-label Safety Study at the Screening/Baseline Visit (Visit 1/Day 1), at which point patient eligibility will be assessed and informed consent obtained.
Conditions
- Major Depressive Disorder
Interventions
LumateperoneDrug
Lumateperone 42 mg capsules administered orally, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number and Percentage of Patients Reporting Treatment Emergent Adverse EventsTime frame: 26 weeks
Locations
109 sites in 11 countries. Site status is shown where the registry gives one.
Clinical Site
Phoenix, Arizona
Clinical Site
Bentonville, Arkansas
Clinical Site
Little Rock, Arkansas
Clinical Site
Rogers, Arkansas
Clinical Site
Culver City, California
Clinical Site
Glendale, California
Clinical Site
Newport Beach, California
Clinical Site
Oceanside, California
Clinical Site
Redlands, California
Clinical Site
Riverside, California
Clinical Site
San Diego, California
Clinical Site
Sherman Oaks, California
Clinical Site
Temecula, California
Clinical Site
Upland, California
Clinical Site
Fort Lauderdale, Florida
Clinical Site
Jacksonville, Florida
Clinical Site
Orlando, Florida
Clinical Site
Palm Bay, Florida
Clinical Site
West Palm Beach, Florida
Clinical Site
Atlanta, Georgia
Clinical Site
Atlanta, Georgia
Clinical Site
Atlanta, Georgia
Clinical Site
Decatur, Georgia
Clinical Site
Joliet, Illinois
Clinical Site
Overland Park, Kansas
Clinical Site
Gaithersburg, Maryland
Clinical Site
Boston, Massachusetts
Clinical Site
Flowood, Mississippi
Clinical Site
Saint Charles, Missouri
Clinical Site
Berlin, New Jersey
Clinical Site
Toms River, New Jersey
Clinical Site
Brooklyn, New York
Clinical Site
Cedarhurst, New York
Clinical Site
Mount Kisco, New York
Clinical Site
Charlotte, North Carolina
Clinical Site
Allentown, Pennsylvania
Clinical Site
Media, Pennsylvania
Clinical Site
Plymouth Meeting, Pennsylvania
Clinical Site
Austin, Texas
Clinical Site
Bellevue, Washington
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.